Nociceptin (Orphanin FQ)

Nociceptin (also called Orphanin FQ, N/OFQ) is a 17-amino acid neuropeptide (Phe-Gly-Gly-Phe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-Leu-Ala-Asn-Gln) discovered simultaneously in 1995 by two groups: Meunier et al. (named "nociceptin" for its pain-facilitating spinal effects) and Reinscheid et al. (named "orphanin FQ" for being the ligand of the orphan ORL1 receptor with Phe and Gln terminal residues). It is the endogenous ligand for the NOP receptor (nociceptin/orphanin FQ peptide receptor, formerly ORL1), which was identified as the fourth opioid receptor based on structural homology to mu, delta, and kappa opioid receptors.

Despite its structural resemblance to the opioid peptide dynorphin A (sharing the Phe-Gly-Gly-Phe N-terminal motif), nociceptin has fundamentally different pharmacology: it does not bind classical opioid receptors (MOR, DOR, KOR) and has unique, site-dependent effects on pain.

**Site-dependent pain effects (the paradox):** - **Supraspinal (ICV)**: Nociceptin produces analgesia via NOP receptors in the brain (PAG, rostroventromedial medulla, amygdala) - **Spinal (intrathecal)**: Nociceptin is pronociceptive — it blocks morphine analgesia and enhances pain sensitivity. This is why it was named "nociceptin" (pain-producing) - The net effect of systemic nociceptin reflects the balance between supraspinal antinociception and spinal pronociception

**Anti-opioid and drug tolerance:** One of the most pharmacologically important properties of nociceptin is its ability to block mu-opioid receptor-mediated analgesia at the spinal level. NOP activation inhibits the analgesic efficacy of morphine. Conversely, NOP antagonists can restore or enhance opioid analgesia. This anti-opioid interaction at the spinal cord is mechanistically relevant to opioid tolerance: chronic morphine increases nociceptin/NOP signaling, which then reduces morphine efficacy — a potential driver of tolerance.

**Psychiatric and stress research:** NOP receptors are highly expressed in limbic and stress-related circuits. NOP agonism: - Reduces CRF-mediated anxiety responses in multiple animal models - Attenuates stress-induced drug seeking and relapse behavior in addiction models - Produces context-dependent effects on depression-like behavior (may be anxiolytic at lower doses, depressive at higher doses)

Buprenorphine, widely used for opioid use disorder (OUD) treatment, is a partial agonist at MOR, KOR antagonist, and moderate NOP partial agonist. Its NOP component is believed to contribute to its atypical pharmacological profile (reduced euphoria, better side effect profile vs full opioid agonists).

Cebranopadol, a mixed MOR/NOP full agonist, is in clinical development for severe pain and OUD — combining opioid analgesia with NOP agonism's addiction-attenuating properties.